Российское диализное общество

Просмотр статьи

<< Вернуться к списку статей журнала

Том 12 №4 2010 год - Нефрология и диализ

О целевых значениях артериального давления у больных ХБП (Обзор литературы)


Ермоленко В.М. Филатова Н.Н.

Аннотация: В кратком обзоре обсуждаются вопросы целевых значений АД у больных хронической болезнью почек. Анализ немногочисленных рандомизированных контролируемых исследований свидетельствует, что декларируемые в зарубежных и отечественных рекомендациях целевые значения АД (<130/80 мм рт. ст.) оптимальны в плане замедления прогрессирования нефропатий и профилактики сердечно-сосудистых осложнений. В то же время, умеренные отклонения у некоторых категорий пациентов от целевых значений АД не влияют на прогноз, тогда как чрезмерная антигипертензивная терапия чревата развитием серьезных осложнений.

Весь текст



Ключевые слова: хроническая болезнь почек, артериальное давление, целевые значения, кардиоваскулярный риск, нефропротекция, ингибиторы ангиотензин-превращающего фермента, блокаторы рецепторов ангиотензина II, chronic kidney disease, nephroprotection, blood pressure, target values, cardiovascular risk, ACE inhibitors, blockers receptors of angiotensin II

Список литературы:
  1. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр) // Кардиоваскулярная терапия и профилактика. 2008. Т. 3 (приложение 2). С. 1–30.
  2. Стаценко М.Е., Щербакова Т.Г., Беленкова С.В., Спорова О.Е. Длительная терапия индапамидом больных артериальной гипертонией пожилого и старческого возраста: возможности кардионефропротекции и влияние на качество жизни // Рациональная фармакотерапия в кардиологии. 2009. № 5. C. 22–27.
  3. Agodoa L., Appel L., Bakris G. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial // JAMA. 2001. Vol. 285 (21). P. 2719–2728.
  4. Alvestrand A., Gutierrez A., Bucht H., Bergstrom J. Reduction of blood pressure retards the progression of chronic renal failure in man // NDT. 1988. Vol. 3. P. 624–631.
  5. Berl T., Hunsicker L., Lewis J. et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 2170–2179.
  6. Bjorck S., Nyberg G., Mules H. et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy // Br. Med. J. 1986. Vol. 293. P. 471–474.
  7. Chobanian A., Bakris G., Black H. et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure // Hypertension. 2003. Vol. 42. P. 1206–1252.
  8. Cicconetti Р., Morelli S., Ottaviani L. et al. Blunted nocturnal fall in blood pressure and left ventricular mass in elderly individuals with recently diagnosed isolated systolic hypertension // Аm. J. Hypertens. 2003. Vol. 16. P. 900–905.
  9. Currie C., Peters J., Tynan A. et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study // Lancet. 2010. Vol. 375, P. 481–489.
  10. Domrongkitchaiporn S., Stritara P., Kityakara C. et al. Risk factors for development of decreased kidney function in a southeast Asia population: a 12-year cohort study // J. Am. Soc. Nephrol. 2005. Vol. 16, P. 791–799.
  11. Estacio R., Coll J., Tran Z., Schrier R. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes // Am. J. Hypertens. 2006. Vol. 19. P. 1241–1248.
  12. Estacio R., Jeffers B., Gifford N., Schrier D. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes // Diabetes Care. 2003. Vol. 23. P 54–64.
  13. Fox K. European trial on reduction of cardiac events with perindopril in stable coronary Artery disease Investigators // Lancet. 2003. Vol. 362. P. 782–788.
  14. Gerber L., Shmukler C., Alderman M. Differences in urinary albumin excretion rate between normotensive and hypertensive white and nonwhite subjects // Arch. Intern. Med. 1992. Vol. 152. P. 373–377.
  15. Hannedouche T., Albouze G., Chauveau P. et al. Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure // Am. J. Kidney Dis. 1993. Vol. 21. P. 131–7.
  16. Hozawa A., Ohkubo T., Nagai K. et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home // Arch. Intern. Med. 2000. Vol. 160. P. 3301–3306.
  17. Ilyas B., Dhaun N., Markie D. et al. Renal function is associated with arterial stiffness and predicts outcome in patients with coronary artery disease // QJM. 2009. Vol. 102. P. 183–191.
  18. Jafar T., Stark P., Schmid C. et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis // Ann. Intern. Med. 2003. Vol. 139. P. 244–252.
  19. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease // Am. J. Kidney. Dis. 2004. Vol. 43. P. 1–90.
  20. Kark М., Karnehed N., Rasmussen Р. Blood pressure in young adulthood and late disability pension. А population-based study оn 867672 men from Sweden // Blood Press. 2007. Vol. 16. P. 362–366.
  21. Klag M., Whelton P., Randall B. et al. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. // 1996. Vol. 334. P. 13–18.
  22. Klahr S., Levey A., Beck G. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease // N. Engl. J. Med. 1994. Vol. 330. P. 877–884.
  23. Kovesdy C., Trivedi B., Kalantar-Zadeh K., Anderson J. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease // NDT. 2006. Vol. 21. P. 1257–1262.
  24. Lazarus M., Bourgoignie J., Buckalew V. et al. Achievement and safety of a low blood pressure goal in chronic renal disease // Hypertension. 1997. Vol. 29. P. 641–650.
  25. Lewis J., Berl T., Bain R. et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy // Am. J. Kidney Dis. 1999. Vol. 34. P. 809–817.
  26. Messerli F., Mancia G., Conti C. et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? // Ann. Intern. Med. 2006. Vol. 144. P. 884–893.
  27. Mule G., Cottone S., Cusimano P. et al. Inverse relationship between ambulatory arterial stiffnes index and glomerular filtration rate in arterial hypertension // Am. J. Hypertens. 2008. Vol. 21. P. 35–40.
  28. National High Blood Pressure Education Program Working Group Report on hypertension and chronic renal failure // Arch. Intern. Med. 1991. Vol. 151. P. 1280–1287.
  29. Palmer B. Management of hypertension in patients with chronic kidney disease and diabetes mellitus // Am. J. Med. 2008. Vol. 121. P. 16–22.
  30. Parving H., Andersen A., Smidt U. et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy // BMJ. 1987. Vol. 294. P. 1443–1447.
  31. Pepine C., Handberg E., Cooper-DeHoff R. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial // JAMA. 2003. Vol. 290. P. 2805–2816.
  32. Perry H., Miller P., Fornoff J. et al. Early predictors of 15-year end-stage renal disease in hypertensive patients // Hypertension. 1995. Vol. 25. P. 587–594.
  33. Peterson J., Adler S., Burkart J. et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study // Ann. Intern. Med. 1995. Vol. 123. P. 754–762.
  34. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack // Lancet. 2001. Vol. 358. P. 1033–1041.
  35. Ruggenenti P., Perna A., Loriga G. et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial // Lancet. 2005. Vol. 365. P. 939–946.
  36. Schernthaner G., Barnett A., Betteridge D. et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis // Diabetologia. 2010. Vol. 53. P. 1258–1269.
  37. Shulman N., Ford C., Hall W. et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The hypertension detection and follow-up program cooperative group // Hypertension. 1989. Vol. 13. P. 180–193.
  38. Sleight P., Redon J., Verdecchia P. et al. Prognostic value of blood pressure in patients with high vascular risk in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study // J. Hypertens. 2009. Vol. 27. P. 1360–1369.
  39. Staessen J., Gasowski J., Wong J. et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials // Lancet. 2000. Vol. 355. P. 865–872.
  40. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes // BMJ. 1998. Vol. 317. P. 703–20.
  41. Verdeccia Р., Staessen J., Angeli F. et al. Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): аn open-label randomized trial // Lancet. 2009. Vol. 374. P. 525–533.
  42. Young J., Klag M., Muntmer P. et al. Blood pressure and decline in kidney function from the Systolic Hypertension in Elderly Program (SHEP) // J. Am. Soc. Nephrol. 2002. Vol. 13. P. 2776–2782.

Другие статьи по теме


Навигация по статьям
Разделы журнала
Наиболее читаемые статьи
Журнал "Нефрология и диализ"